Its SkinBiotix cream was assessed for cellular toxicity and specifically for adverse biological reactions from mammalian cell cultures.
READ: SkinBioTherapeutics - New listing in the emerging field of the human microbiome has multiple value trigger points
SkinBio said no cytotoxicity was observed; in other words there was no malformation of cells, or cell degeneration.
The data backed up in-house results compiled by the company, which listed on the stock market in April.
“This was one of the key milestones to pass and was highlighted as such at the IPO,” said chief executive, Dr Catherine O’Neill.
“Its passing marks a critical step in our progression and the transitioning of the technology into human validation studies.”
The SkinBiotix platform is protected by three patent families and 18 patent applications and is supported by a host of peer-reviewed academic publications and has been developed to enhance the skin cell barrier, protect the skin and aid its regeneration.
From that it is developing three products that manage, protect and restore the body’s largest organ.
First cab off the rank will be the company’s cosmetic for sensitive skin, which should be properly formulated towards the end of this year, before entering human studies in the second-quarter of next.
Going into development in the third-quarter of next year is a prophylactic for healthcare acquired infections.
The company hopes to begin commercialising the protective hand cream in 2020, the same year as work begins on an eczema treatment.
The research and development group, which is focused on understanding the skin-based portion human microbiome, said it had made a number of key advances in recent months as it updated on the progress of its three programmes.
Pilot formulation has begun with an outside partner with expertise in cosmetics. Phase one of three is complete: testing the solubility and preservative requirements of the technology. Phase two, identifying a final blend for testing, is currently underway.
At the same time, a study has determined the cream is best applied every five hours for protection against infection.
In the update, SkinBioTherapeutics said it had finalised a dosing level at which the technology will be used which maintains the viability of the skin cells.
It has also received confirmation of the modifying property of SkinBiotix on the protein composition of the skin, increasing the expression of a protein called Claudin 4 that help protect the skin.
Early-stage commercial discussions have also begun with both would-be licensees and manufacturers.
"Operationally, we are on track,” said CEO O’Neill. “The development programmes are progressing well, we are generating further scientific data on SkinBiotix confirming its suitability for application to skin, and industry awareness of our technology is growing."